CR CRL Charles River Laboratories International, Inc. Загрузка... : Бычьи и медвежьи мнения аналитиков

Charles River signals plans to pursue additional mergers and acquisitions by adding new.

Charles River Laboratories raises its full-year profit forecast and guidance.

IQVIA disclosed a new customer segment breakdown, with EVP (emerging biopharma) being a much larger part of revenue (35%) than previously disclosed, positioning them as the largest EVP provider. — Signals potential re-rating of IQVIA's growth vs. peers, as EVP segment is growing 2-3x faster than large pharma, suggesting structural advantage over other CROs.

Management reaffirmed all guidance, acknowledging a challenged start but pointing to a significant margin expansion in the second half driven by acquisitions, divestitures, and cost savings. The tone is cautiously optimistic about demand recovery, but the full-year outlook remains unchanged, pointing to a neutral stance.

The author compares current semiconductor mania to the COVID-era biopharma bubble.

The author compares current semiconductor mania to the COVID-era life sciences bubble.

A significant target price reduction from a sell-side bank implies a deteriorating outlook.

Despite continued revenue decline in 2026, management sees demand stabilization and is guiding to margin expansion, implying a trough and turnaround story for 2026.

IQVIA noted that cancellations in Q4 were 'slightly above the normal range' due to idiosyncratic reasons, but overall demand metrics (pipeline, RFP flow, win rates) improved, and backlog reached a record high. — Despite a slightly elevated cancellation rate, the strong bookings and growth in backlog indicate a healthy overall demand environment for clinical research services, a positive signal for the whole CRO sector.